newsfilter
← Latest News
GlobeNewswire·

Serina Therapeutics Advances POZ-VMAT2i into Development for Tardive Dyskinesia (TD)

- Novel once-weekly injectable VMAT2 inhibitor targets underserved patients with serious adherence and access challenges – - Potential expansion into Huntington's chorea – an underserved indication with high need for